The following symptoms may occur in newborn babies, of mothers that have used prochlorperazine tablets in the last trimester last three months of their pregnancy: If your baby develops any of these symptoms you may need to contact your doctor. Driving and using machines Prochlorperazine tablets may cause drowsiness. Make sure you are not affected before you drive or operate machinery. Prochlorperazine tablets contains lactoe If you have been told you have an intolerance to some sugars, contact your doctor before taking this medicine, as it contains a type of sugar called lactose.

Check with your doctor or pharmacist if you are not sure. Swallow the tablets with water. Prochlorperazine is also available to buy over-the-counter from pharmacies. It comes as a buccal tablet dissolves in the mouth that is used to relieve sickness caused by migraine. Before taking prochlorperazine Some medicines are not suitable for people with certain conditions, and sometimes a medicine may only be used if extra care is taken.

For these reasons, before you start taking prochlorperazine it is important that your doctor knows: If you are pregnant or breast-feeding. If you have a heart condition or blood vessel disease. If you have liver, kidney, or prostate problems.

If you have breathing problems. If you have problems with your thyroid gland. If you have any of the following: If you have ever had yellowing of your skin or the whites of your eyes jaundice or a blood disorder. If you have a tumour on your adrenal gland, a condition called phaeochromocytoma. If you have ever had an allergic reaction to a medicine. Carefully monitor the patient for hypotension, CNS depression, and respiratory depression.

Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. Also, hydromorphone may cause severe hypotension which can be exacerbated by drugs that compromise vasomotor tone, such as phenothiazines. Minor Use caution with the coadministration of hydroxychloroquine and prochlorperazine. Hydroxychloroquine increases the QT interval and should not be administered with other drugs known to prolong the QT interval.

Ventricular arrhythmias and torsade de pointes have been reported with the use of hydroxychloroquine. Theoretically, prochlorperazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation, such as hydroxychloroquine.

Fluphenazine, perphenazine, prochlorperazine, and trifluoperazine are associated with a possible risk for QT prolongation. Theoretically, these agents may increase the risk of QT prolongation if coadministered with drugs with a risk of QT prolongation. In addition, the anticholinergic effects of hydroxyzine are moderate and may be enhanced when combined with other antimuscarinics.

Other commonly used drugs with moderate to significant anticholinergic effects include most phenothiazines. Clinicians should note that antimuscarinic effects might be seen not only on GI smooth muscle, but also on bladder function, the eye, and temperature regulation.

Additive drowsiness may also occur. Concurrent use of drugs that are associated with a possible risk for QT prolongation and torsade de pointes TdP , such as ibutilide, with prochlorperazine should be approached with caution. Ibutilide administration can cause QT prolongation and TdP; proarrhythmic events should be anticipated.

The potential for proarrhythmic events with ibutilide increases with the coadministration of other drugs that prolong the QT interval. According to the manufacturer, iloperidone should be avoided in combination with other drugs having an association with QT prolongation.

Moderate Indapamide may cause electrolyte disturbances, which may increase the potential for proarrhythmic effects of selected phenothiazines.

Minor Coadministration of inotuzumab ozogamicin with prochlorperazine may increase the potential for additive QT prolongation and risk of torsade de pointes TdP. Inotuzumab has been associated with QT interval prolongation.

Minor Monitor patients receiving insulin closely for worsening glycemic control when phenothiazines are instituted. The phenothiazines, especially chlorpromazine, may increase blood glucose concentrations. Major Use of medications that lower the seizure threshold should be carefully evaluated when considering the use of intrathecal radiopaque contrast agents.

Phenothiazines should be discontinued at least 48 hours before myelography and should not be resumed for at least 24 hours postprocedure. Major Ipecac has been shown to be effective in producing emesis in patients who have ingested antiemetics, provided ipecac is given promptly usually within 1 hour of antiemetic consumption.

If ipecac is administered after antiemetic therapy has begun to exert therapeutic effects, ipecac may be less effective. It is suggested the irritating GI effects of ipecac lead to emesis following antiemetic consumption. Minor Of 47 patients who received prochlorperazine on the same day as irinotecan, 4 had akathisia as compared with 1 of 80 patients who received the drugs on different days. Patients received the weekly irinotecan dosage schedule. Of note, the 8. Major Rifamycins can increase the metabolism or reduce the bioavailability of phenothiazines.

Dosage increases of phenothiazines may be necessary following the addition of rifampin or another rifamycin. Minor Itraconazole has been associated with prolongation of the QT interval. Drugs that should be used cautiously and with close monitoring with itraconazole include prochlorperazine. Kava Kava, Piper methysticum: Moderate Use kava kava with caution when patients are taking phenothiazines like prochlorperazine.

Additive sedation and CNS effects are possible. In addition, kava kava has been reported to inhibit many CYP isozymes i. Prochlorperazine is a primary substrate of CYP2D6 and it is not yet documented if pharmacokinetic interactions occur with kava kava.

Moderate Additive CNS effects may occur if prochlorperazine is administered concomitantly with general anesthetics. Minor Ketoconazole has been associated with prolongation of the QT interval. Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with ketoconazole include prochlorperazine.

Major The phenothiazines, including prochlorperazine, can lower the seizure threshold. Major Oral compounds known to interact with antacids, like phenothiazines, should not be taken within 2 hours of dosing with lanthanum carbonate.

If these agents are used concomitantly, space the dosing intervals appropriately. Monitor serum concentrations and clinical condition.

Minor Lapatinib can prolong the QT interval. Lapatinib should be administered with caution to patients who have or may develop prolongation of QTc such as patients taking anti-arrhythmic medicines or other medicinal products that lead to QT prolongation. Administer lapatinib with caution in patients taking drugs with the potential to induce QT prolongation. Drugs with a possible risk for QT prolongation and torsade de pointes TdP that should be used cautiously and with close monitoring with lapatinib include prochlorperazine.

Minor Androgen-deprivation therapy e. This risk is generally higher at elevated drugs concentrations of phenothiazines. Agents that prolong the QT interval could lead to torsade de pointes when combined with a phenothiazine, and therefore are generally not recommended for combined use; if they must be used, use with caution and with close monitoring.

Also, drugs that cause hyperprolactinemia, such as antipsychotics, should be used with caution with gonadotropin releasing hormone GnRH analogs e. Minor Concurrent use of prochlorperazine and levofloxacin should be avoided due to an increased risk for QT prolongation and torsade de pointes TdP.

Levofloxacin has also been associated with prolongation of the QT interval and infrequent cases of arrhythmia. Additionally, rare cases of TdP have been spontaneously reported during postmarketing surveillance in patients receiving levofloxacin. Levomethadyl is contraindicated in combination with other agents that may prolong the QT interval, including the phenothiazines. Moderate Some atypical antipsychotics are considered first-line adjunctive therapy to mood stabilizers such as lithium.

Because both prochlorperazine and lithium have been associated with QT prolongation, coadminister cautiously and with close monitoring. It is also advisable to monitor patients for neurotoxicity during co-administration. Neuroleptic malignant syndrome NMS has been observed occasionally during concurrent use of lithium and either atypical or conventional antipsychotics. Additive extrapyramidal effects have also been noted.

Early case reports described an encephalopathic syndrome consisting of delirium, tremulousness, dyskinesia, seizures, leukocytosis, weakness, hyperpyrexia, confusion, extrapyramidal symptoms, elevations in laboratory values e. Subsequent rare reports of NMS or NMS-like reactions have been described during co-administration of lithium and atypical antipsychotics e.

Following resolution of NMS, there are isolated instances of re-emergence of symptoms following re-initiation of lithium as monotherapy. Lithium may be a risk factor for antipsychotic-induced NMS; however, this hypothesis has not been confirmed.

In many reported cases, confounding factors have been present e. The ability of antipsychotics alone to precipitate NMS and the rarity of the condition further complicate assessment of lithium as a risk factor.

Minor Phenothiazines may cause additive photosensitization with quinolones. Patients should take care and use proper techniques to limit sunlight and UV exposure.

Theoretically, prochlorperazine may increase the risk of QT prolongation if coadministered with drugs with a risk of QT prolongation. At high doses, loperamide has been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, torsade de pointes TdP , and cardiac arrest. In addition, both drugs may decrease gastrointestinal GI motility; concurrent use could produce additive GI effects and induce toxic megacolon.

If these drugs are given together, monitor for prolongation of the QT interval and for signs of impaired intestinal motility. Minor Due to the potential for QT prolongation and torsade de pointes TdP , caution is advised when administering lopinavir; ritonavir with prochlorperazine.

Lopinavir; ritonavir is associated with QT prolongation. Major Alchemy level 2 DIs- stop at loaxapine and iloperidone for loxapine and antipsychotic interaction. Loxapine use has been associated with adverse events such as drowsiness, dizziness, orthostatic hypotension, anticholinergic effects, extrapyramidal symptoms, neuroleptic malignant syndrome, and seizures.

These effects may be potentiated during concurrent use of loxapine and other antipsychotics. Major Similar to other antipsychotics, lurasidone administration has been associated with drowsiness, dizziness, orthostatic hypotension, extrapyramidal symptoms, neuroleptic malignant syndrome, and seizures.

The risk of these adverse effects may be increased during concurrent use of lurasidone with other antipsychotics. Minor Because of the CNS-depressant effects of magnesium sulfate, additive central-depressant effects can occur following concurrent administration with CNS depressants such as phenothiazines. Caution should be exercised when using these agents concurrently. Because maprotiline is associated with a possible risk for QT prolongation and torsade de pointes TdP , concurrent use with prochlorperazine should be approached with caution.

In addition, additive anticholinergic effects may be seen when phenothiazines are used concomitantly with other drugs with antimuscarinic activity such as maprotiline. Moderate Additive effects may be seen when phenothiazines are used concomitantly with other drugs with antimuscarinic activity, such as meclizine, a sedating H1-blocker. Minor Due to the potential for QT prolongation and torsade de pointes TdP , caution is advised when administering prochlorperazine with mefloquine.

There is evidence that the use of halofantrine after mefloquine causes significant lengthening of the QTc interval. Mefloquine alone has not been reported to cause QT prolongation; however due to the lack of clinical data, mefloquine should be used with caution in patients receiving drugs that prolong the QT interval. Moderate Melatonin may exhibit pharmacodynamic interactions with the phenothiazines. Melatonin has been co-administered in studies with thioridazine.

No clinically significant pharmacokinetic interactions were found. However, melatonin co-administration resulted in increased feelings of cognitive impairment compared to thioridazine alone. Patients may need to be informed of the possibility of additive central nervous system CNS effects, such as sedation, dizziness, and CNS impairment. Major Phenothiazines can potentiate the CNS-depressant action of other drugs such as meperidine.

Minor Prochlorperazine should be used cautiously and with close monitoring with methadone. The need to coadminister methadone with drugs known to prolong the QT interval should be done with extreme caution and a careful assessment of treatment risks versus benefits.

Laboratory studies, both in vivo and in vitro, have demonstrated that methadone inhibits cardiac potassium channels and prolongs the QT interval.

Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. In addition, phenothiazines can potentiate the CNS-depressant action of methadone.

If concurrent use is necessary, closely monitor patients for signs or symptoms of skin toxicity. Major The phenothiazines, when used concomitantly with anticonvulsants, can lower the seizure threshold.

Moderate Antipsychotics, such as phenothiazines, and methylphenidate may interact pharmacodynamically to diminish the therapeutic effects of either agent through opposing effects on dopamine. Methylphenidate blocks central dopamine reuptake, which has the potential to exacerbate psychosis, and antipsychotics, which are central dopamine antagonists, may diminish the effectiveness of methylphenidate. Severe Metoclopramide is a central dopamine antagonist and may cause extrapyramidal reactions e.

Metoclopramide is contraindicated with other drugs that are likely to cause extrapyramidal effects since the risk of these effects may be increased. Phenothiazine antiemetics are also central dopamine antagonists and have been associated with extrapyramidal symptoms and rarely, neuroleptic malignant syndrome. In addition, because both phenothiazines and metoclopramide can cause sedation, seizures, or increased prolactin levels, it is possible that the risk of these effects may be increased during concurrent use.

The manufacturer of metoclopramide does not specifically contraindicate the use of metoclopramide and phenothiazine antiemetics; however, coadministration should generally be avoided if possible.

Other drugs that may also cause drowsiness, such as phenothiazines, should be used with caution. Moderate Because it also blocks central dopamine receptors, metyrosine should be avoided or used cautiously in patients receiving a phenothiazine to minimize the risk of additive adverse CNS effects. A dose reduction may be required if combination therapy is necessary.

Minor The concomitant use of midostaurin and prochlorperazine may lead to additive QT interval prolongation. If these drugs are used together, consider electrocardiogram monitoring. In clinical trials, QT prolongation has been reported in patients who received midostaurin as single-agent therapy or in combination with cytarabine and daunorubicin.

Additionally, prochlorperazine is associated with a possible risk for QT prolongation. Prochlorperazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation. Minor Due to a possible risk for QT prolongation and torsade de pointes TdP , mifepristone and prochlorperazine should be used together cautiously.

Mifepristone has been associated with dose-dependent prolongation of the QT interval. There is no experience with high exposure or concomitant use with other QT prolonging drugs. To minimize the risk of QT prolongation, the lowest effective dose should always be used.

Drugs with a possible risk for QT prolongation and torsades de pointes that should be used cautiously with mifepristone include prochlorperazine. Minor Injectable minocycline contains magnesium sulfate heptahydrate. Because of the CNS-depressant effects of magnesium sulfate, additive central-depressant effects can occur following concurrent administration with CNS depressants such as phenothiazines.

Due to the possibility of additive effects on the QT interval, caution is advisable during concurrent use of mirtazapine and prochlorperazine. Cases of QT prolongation, TdP, ventricular tachycardia, and sudden death have been reported during postmarketing use of mirtazapine. The majority of reports have occurred in the setting of mirtazapine overdose or in patients with other risk factors for QT prolongation, including concomitant use of other medications associated with QT prolongation.

Because both mirtazapine and prochlorperazine have CNS depressant properties, patients should be advised to avoid engaging in activities requiring mental alertness until they are aware of the effects of the combination. Moderate Mitotane can cause sedation, lethargy, vertigo, and other CNS side effects. Concomitant administration of mitotane and CNS depressants, including opiate agonists, may cause additive CNS effects. Major Close monitoring is advisable during concurrent use of molindone with other antipsychotics.

Because molindone shares certain pharmacological properties with other antipsychotics, additive cardiac effects e. Major Concurrent use of MAOIs and phenothiazines may prolong or intensify the hypotensive, anticholinergic, or sedative effects of either agent. Moderate Concomitant use of morphine with other CNS depressants can potentiate the effects of morphine on respiration, blood pressure, and alertness.

Severe hypotension may occur if morphine is administered to a patient taking phenothiazines. Profound sedation and coma may also occur. Prior to use of morphine in patients taking a CNS depressant, assess the level of tolerance to CNS depression that has developed, the duration of use, and the patient's overall response to treatment.

Minor Concurrent use of prochlorperazine and moxifloxacin should be avoided due to an increased risk for QT prolongation and torsade de pointes TdP. Moxifloxacin has also been associated with prolongation of the QT interval. Additionally, post-marketing surveillance has identified very rare cases of ventricular arrhythmias including TdP, usually in patients with severe underlying proarrhythmic conditions.

The likelihood of QT prolongation may increase with increasing concentrations of moxifloxacin, therefore the recommended dose or infusion rate should not be exceeded. Moderate Concomitant use of nabilone with other CNS depressants, including phenothiazines, can potentiate the effects of nabilone on respiratory depression. Moderate Antipsychotics may cause hyperprolactinemia and should not be administered concomitantly with nafarelin since hyperprolactinemia down-regulates the number of pituitary GnRH receptors.

Moderate Concomitant use of nalbuphine with other CNS depressants, such as phenothiazines, can potentiate the effects of nalbuphine on respiratory depression, CNS depression, and sedation. Minor Coadministration of nilotinib and a drug that prolongs the QT interval is not advised; nilotinib prolongs the QT interval.

If concurrent administration is unavoidable, the manufacturer of nilotinib recommends interruption of nilotinib treatment. If nilotinib must be continued, closely monitor the patient for QT interval prolongation. Drugs with a possible risk for QT prolongation and torsade de pointes TdP that should be avoided in combination with nilotinib include prochlorperazine.

Minor Nitroglycerin can cause hypotension. This action may be additive with other agents that can cause hypotension such as phenothiazines. This drug may increase sensitivity to sunlight. Prolonged exposure to sunlight should be avoided, and a sunscreen and protective clothing should be used when body is exposed to sun.

Prochlorperazine may interfere the thermoregulatory mechanisms and making more susceptible to heat stroke. Therefore, patients should be advised to avoid heat exposure. Prochlorperazine overdose may cause different toxic manifestations including cardiac arrhythmias, hypotension, hypothermia, severe extra pyramidal muscular dystonic reactions, drowsiness, loss of consciousness. If the patient is seen within 6 hours after ingestion of drug, gastric lavage may be attempted.

Activated charcoal may be given. There is no specific antidote of prochlorperazine. I contacted the doctors but was told to take paracetamol and ibuprofen alternatively every 2 hours until the pain subsided. I was then put on the ENT waiting list to see a specialist. In the meantime my parents paid for me to see a consultant as was unable to go to work.

He was very positive after checking my hearing and balance.

Tags: omeprazole 20mg tab perrigo voltaren 75mg 3ml oldatos injekció xanax barsmg oxycodone 10mg np 12

© Copyright 2017 Prochlorperazine maleate 5mg alcohol *** Low Cost Pills.